Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?

• Hoofdauteurs: Özge Kaya (Auteur), Zeynep Keskinkaya (Auteur), Selda Işık Mermutlu (Auteur), Sevilay Oğuz Kılıç (Auteur), Sevgi Öztürk (Auteur)
• Formaat: Boek
• Gepubliceerd in: Mattioli1885, 2023-07-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Introduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era.  Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19 in...